Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2013 16:00 ET | Source: TESARO, Inc.

TESARO Announces Closing of Public Offering and Full Exercise of Over-Allotment Option by Underwriters

WALTHAM, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of common stock. The total number of...
February 28, 2013 07:07 ET | Source: TESARO, Inc.

TESARO Announces Pricing of Upsized Public Offering of Common Stock

WALTHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,720,000 shares of its common stock...
February 25, 2013 06:10 ET | Source: TESARO, Inc.

TESARO Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection...
February 14, 2013 07:07 ET | Source: TESARO, Inc.

TESARO Announces Fourth Quarter and Year-End 2012 Operating Results

Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian Cancer Enrollment Continues in the Global Registration Program for Rolapitant Achieved Third Dose-level in a Phase 1/2...
February 11, 2013 07:05 ET | Source: TESARO, Inc.

TESARO to Announce Fourth Quarter and Year End 2012 Financial Results on Thursday, February 14th, 2013

WALTHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter and year end 2012 financial results on Thursday, February 14th, 2013, before the opening...
February 06, 2013 16:52 ET | Source: TESARO, Inc.

TESARO to Present at the Leerink Swann Global Healthcare Conference

WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
November 29, 2012 15:00 ET | Source: TESARO, Inc.

TESARO to Present at the Deutsche Bank 2012 dbAccess BioFEST

WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific...
November 01, 2012 07:05 ET | Source: TESARO, Inc.

TESARO and Virginia G. Piper Cancer Center Announce Enrollment of First Patient in Clinical Trial of TSR-011

WALTHAM, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has...
October 25, 2012 16:05 ET | Source: TESARO, Inc.

TESARO Announces Third Quarter 2012 Operating Results

Continued Enrollment for the Global Registration Program for Rolapitant Announced Clearance of Investigational New Drug Application for TSR-011 Appointed Robert E. Martell, M.D., Ph.D.,...
October 16, 2012 17:00 ET | Source: TESARO, Inc.

TESARO to Announce Third Quarter 2012 Financial Results on Thursday, October 25th, 2012

WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25th, 2012, after the close of the U.S....